CClinicalTrials.gg
CompletedNCT02949089Updated Oct 31, 2016

ACH04 to Assess the Safety and Tolerability in Healthy Adults Subjects

A Phase 1 interventional study of ACH04 in Diarrhea, sponsored by Ache Laboratorios Farmaceuticos S.A.. Completed at 1 site in Brazil. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-31.

Sponsored by Ache Laboratorios Farmaceuticos S.A. · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

This study intends to provide information on the safety and tolerability of repeated oral doses of ACH04. A phase I, single-center, first in human, open-label, dose escalation study of ACH04 to assess the safety and tolerability in healthy adults subjects is selected to best address the study goals.

02

Conditions studied

  • Diarrhea

Browse trials for

Keywords

  • safety
  • tolerability
  • rising multiple doses
  • ACH04
  • adult
  • male
03

In context

Diarrhea

852 studies on the registry are indexed under Diarrhea; 78 are open to participants now.

This study's enrollment of 60 is below the median of 136 across 713 interventional studies indexed under Diarrhea.

Browse Diarrhea studies →

Lead sponsor

Ache Laboratorios Farmaceuticos S.A. is the lead sponsor of 34 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Subjects will be healthy males subjects between 18 and 50 years of age;
  • Subjects must be in good healthy as determined by a medical history, physical examination and clinical laboratory evaluations;
  • Subjects will, prior to any study related activities, have given their written informed consent to participate in the study and to abide by the stdy restrictions.

Exclusion criteria

Exclusion Criteria:

  • Subjects with hypersensitivity known to Psidium guajava L. or history of serious adverse events;
  • Subjects who have a significant history of alcoholism or drug/chemical abuse;
  • Subjects who have body mass index \< 18 or > 30;
  • Subjects who have received any medications that is known to have a toxic potential well defined in large organs within the past 3 months prior the study start;
  • Subjets who doesn´t agree to use, for the duration of the study, a barrier contraceptive;
  • Subjects who were hospitalized for any reason in the six week prior the study start;
  • Subjects who, in the opinion of the investigator, should not participate in the study, including subjects suspected for whatever reason of not being able to comply with the requirements of the protocol;
  • Subjects who are participating in a clinical trial or have participated in a clinical study involving administration of an investigational drug, within one year;
  • Subjects who are relatives of employees from the sponsor and the site, respectively;
  • Subjects with, or with a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological, dermatological or other major disorders as determined by the Investigator;
  • Any finding of clinical observation (anamnesis and physical evaluation), laboratory abnormality, who in the investigator opinion, may jeopardize the subjects or interfere with the study goals.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    ACH04

    Dosage: 1 capsule, PO, 24/24h for 10 days.

    Drug: ACH04

Interventions

  • DrugACH04

    The subjects will receive the study medication in each group

06

What researchers measure

Primary outcomes

  1. Evaluate the safety of rising multiple doses of ACH04

    Evaluate the occurrence of adverse events, Assess safety through laboratory tests and Assess safety through electrocardiogram

    Time frame: up to 39 days

07

Study locations

1 site
  • UNIFAC
    Fortaleza, Ceará 60160140, Brazil
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 31, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02949089
Lead sponsor
Ache Laboratorios Farmaceuticos S.A.
Responsible party
Sponsor
First posted
Oct 31, 2016
Start date
Jan 2013
Primary completion
Sep 2014
Completion
Sep 2014
Last update
Oct 31, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion